2020 ASCO Virtual Direct™ Highlights

 

2020 ASCO Virtual Direct™ Highlights
S

2020 ASCO Highlights on HER2+ mCRC: Is Promising Trastuzumab Deruxtecan Active in Disease Refractory to Standard Therapies?

By 2020 ASCO Virtual Direct™ Highlights FEATURING Shikha Jain
By 2020 ASCO Virtual Direct™ Highlights FEATURING Shikha Jain
131 views
July 16, 2020
0 Comments
Login to view comments. Click here to Login

Featured Video

17:33
AstraZeneca Oncology

First-line Maintenance Therapy for BRCAm Advanced Ovarian Cancer Fol…

Feat. S. Lewin

Featured Video

06:51
Insights from 2023 ASH Annual Meeting

ASH 2023 Insights: "Prevalence and Prediction of Ruxolitinib Tr…

Feat. D. Tremblay
GI
08:05
2020 ASCO Virtual Direct™ Highlights

2020 ASCO Highlights on HER2+ mCRC: Is Promising Trastuzumab Deruxte…

Feat. S. Jain
06:45
2020 ASCO Virtual Direct™ Highlights

2020 ASCO Highlights on BRAF V600E Mutant mCRC: Does FDA Approved En…

Feat. S. Jain
08:01
2020 ASCO Virtual Direct™ Highlights

2020 ASCO Highlights on Stage III CRC: Is There a Difference in 5 yr…

Feat. S. Jain
06:48
2020 ASCO Virtual Direct™ Highlights

2020 ASCO Highlights on CRC: Can We Consider Pembrolizumab a New Fir…

Feat. S. Jain
19:45
2020 ASCO Virtual Direct™ Highlights

2020 ASCO Pancreatic Cancer Highlights: Is Perioperative mFOLFIRINOX…

Feat. H. Soares
11:51
2020 ASCO Virtual Direct™ Highlights

2020 ASCO Highlights on Esophageal / Gastric Cancers: Did Trastuzuma…

Feat. H. Soares
05:29
2020 ASCO Virtual Direct™ Highlights

2020 ASCO Highlights on HCC: Donafenib vs. Sorafenib - Which Combina…

Feat. H. Soares